This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Celgene Corporation.
Reference
Lee D, et al. The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q. PharmacoEconomics-Open : 14 Dec 2018. Available from: URL: https://doi.org/10.1007/s41669-018-0110-3
Rights and permissions
About this article
Cite this article
Addressing uncertainty in cost-effectiveness case for lenalidomide. PharmacoEcon Outcomes News 819, 4 (2019). https://doi.org/10.1007/s40274-019-5543-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5543-0